20 results on '"Emma Tomlinson"'
Search Results
2. Pomegranate protects liver against cecal ligation and puncture-induced oxidative stress and inflammation in rats through TLR 4 /NF‐κB pathway inhibition
- Author
-
El-Sayed M. Ammar, Mirhan N. Makled, Nariman M. Gameil, Rania R. Abdelaziz, Nadia Atwan, Emma Tomlinson Guns, Mohammed S. El-Awady, and Ahmed B. Shehab El-Din
- Subjects
0301 basic medicine ,Health, Toxicology and Mutagenesis ,Anti-Inflammatory Agents ,Inflammation ,Punctures ,Pharmacology ,Protective Agents ,Toxicology ,medicine.disease_cause ,Antioxidants ,Proinflammatory cytokine ,Lipid peroxidation ,Sepsis ,03 medical and health sciences ,chemistry.chemical_compound ,0302 clinical medicine ,medicine ,Animals ,Cecum ,Ligation ,Lythraceae ,Plant Extracts ,business.industry ,NF-kappa B ,General Medicine ,Glutathione ,medicine.disease ,Malondialdehyde ,Rats ,Oxidative Stress ,030104 developmental biology ,Liver ,chemistry ,030220 oncology & carcinogenesis ,Immunology ,Tumor necrosis factor alpha ,medicine.symptom ,business ,Oxidative stress - Abstract
Acute liver injury secondary to sepsis is a major challenge in intensive care unit. This study was designed to investigate potential protective effects of pomegranate against sepsis-induced acute liver injury in rats and possible underlying mechanisms. Pomegranate was orally given (800mg/kg/day) for two weeks before sepsis induction by cecal ligation and puncture (CLP). Pomegranate improved survival and attenuated liver inflammatory response, likely related to downregulation of mRNA expression of toll like recptor-4, reduced nuclear translocation and DNA binding activity of proinflammatory transcription factor NF-κB subunit p65, decreased mRNA and protein expression of tumor necrosis factor-alpha and reduction in myeloperoxidase activity and mRNA expression. Pomegranate also decreased CLP-induced oxidative stress as reflected by decreased malondialdehyde content, and increased reduced glutathione level and superoxide dismutase activity. These results confirm the antiinflammatory and antioxidant effects of pomegranate in CLP-induced acute liver injury mediated through inhibiting TLR4/NF-κB pathway, lipid peroxidation and neutrophil infiltration.
- Published
- 2016
- Full Text
- View/download PDF
3. Large oncosomes contain distinct protein cargo and represent a separate functional class of tumor-derived extracellular vesicles
- Author
-
Michael R. Freeman, Chiara Ciardiello, Valentina R. Minciacchi, Matteo Morello, Mandana Zandian, Su Chul Jang, Geetanjali Kharmate, Dae-Kyum Kim, Samantha Morley, Cristiana Spinelli, Emma Tomlinson Guns, Dolores Di Vizio, Elham Hosseini-Beheshti, Lorenzo Cavallini, Sungyong You, Wei Yang, Martin E. Gleave, Mariana Sobreiro, Yong Song Gho, Paul Joseph Aspuria, and Suresh Mathivanan
- Subjects
Male ,Proteomics ,Pathology ,medicine.medical_specialty ,Glutamine ,Glutamine metabolism ,Formins ,Centrifugation ,Biology ,Transfection ,Bioinformatics ,Extracellular vesicles ,Mice ,Extracellular Vesicles ,03 medical and health sciences ,Prostate cancer ,0302 clinical medicine ,Cell-Derived Microparticles ,Tandem Mass Spectrometry ,Cell Line, Tumor ,Biomarkers, Tumor ,medicine ,Animals ,Humans ,Chromatography, High Pressure Liquid ,Adaptor Proteins, Signal Transducing ,Amoeboid blebbing ,030304 developmental biology ,SILAC Proteomics ,Chromatography, Reverse-Phase ,0303 health sciences ,Keratin-18 ,Prostatic Neoplasms ,Cancer ,Urological Diseases ,medicine.disease ,Cancer metabolism ,Tumor progression ,Molecular science ,Neoplasm Proteins ,3. Good health ,Protein Transport ,Oncology ,030220 oncology & carcinogenesis ,Organelle Size ,RNA Interference ,Research Paper - Abstract
// Valentina R. Minciacchi 1 , Sungyong You 1 , Cristiana Spinelli 1 , Samantha Morley 2 , Mandana Zandian 1 , Paul-Joseph Aspuria 3 , Lorenzo Cavallini 1,4 , Chiara Ciardiello 1,5 , Mariana Reis Sobreiro 1 , Matteo Morello 1 , Geetanjali Kharmate 6 , Su Chul Jang 7 , Dae-Kyum Kim 7 , Elham Hosseini-Beheshti 6 , Emma Tomlinson Guns 6 , Martin Gleave 6 , Yong Song Gho 7 , Suresh Mathivanan 8 , Wei Yang 1 , Michael R. Freeman 1,2 and Dolores Di Vizio 1,2 1 Division of Cancer Biology and Therapeutics, Departments of Surgery, Biomedical Sciences and Pathology and Laboratory Medicine, Samuel Oschin Comprehensive Cancer Institute, Cedars-Sinai Medical Center, Los Angeles, CA, USA 2 The Urological Diseases Research Center, Boston Children’s Hospital, Boston, MA, Department of Surgery, Harvard Medical School, Boston, MA, USA 3 Women’s Cancer Program, Cedars-Sinai Medical Center, Los Angeles, CA, USA 4 Department of Experimental and Clinical Biomedical Science, University of Florence, Florence, Italy 5 Experimental Pharmacology Unit, Department of Research, IRCCS-Istituto Nazionale Tumori G. Pascale, Naples, Italy 6 Vancouver Prostate Centre, Department of Urologic Sciences, University of British Columbia, BC, Canada 7 Department of Life Sciences, Pohang University of Science and Technology, Pohang, Republic of Korea 8 Department of Biochemistry, La Trobe Institute for Molecular Science, La Trobe University, Bundoora, Australia Correspondence to: Dolores Di Vizio, email: // Keywords : Extracellular Vesicles, SILAC Proteomics, Cancer metabolism, Tumor progression, Amoeboid blebbing Received : January 05, 2015 Accepted : February 22, 2015 Published : March 14, 2015 Abstract Large oncosomes (LO) are atypically large (1-10µm diameter) cancer-derived extracellular vesicles (EVs), originating from the shedding of membrane blebs and associated with advanced disease. We report that 25% of the proteins, identified by a quantitative proteomics analysis, are differentially represented in large and nano-sized EVs from prostate cancer cells. Proteins enriched in large EVs included enzymes involved in glucose, glutamine and amino acid metabolism, all metabolic processes relevant to cancer. Glutamine metabolism was altered in cancer cells exposed to large EVs, an effect that was not observed upon treatment with exosomes. Large EVs exhibited discrete buoyant densities in iodixanol (OptiPrep TM ) gradients. Fluorescent microscopy of large EVs revealed an appearance consistent with LO morphology, indicating that these structures can be categorized as LO. Among the proteins enriched in LO, cytokeratin 18 (CK18) was one of the most abundant (within the top 5 th percentile) and was used to develop an assay to detect LO in the circulation and tissues of mice and patients with prostate cancer. These observations indicate that LO represent a discrete EV type that may play a distinct role in tumor progression and that may be a source of cancer-specific markers.
- Published
- 2015
- Full Text
- View/download PDF
4. Identification of a Potent Antiandrogen that Targets the BF3 Site of the Androgen Receptor and Inhibits Enzalutamide-Resistant Prostate Cancer
- Author
-
Emma Tomlinson Guns, Nada Lallous, Jon Paul Selvam Jonadass, Hans Adomat, Christophe André, Michael Hsing, Fuqiang Ban, Amina Zoubeidi, Paul S. Rennie, Mohamed D.H. Hassona, Kate Frewin, Dennis Ma, Robert N. Young, Artem Cherkasov, Eric Leblanc, Kriti Singh, and Ravi Shashi Nayana Munuganti
- Subjects
Male ,Indoles ,medicine.drug_class ,Transplantation, Heterologous ,Clinical Biochemistry ,Mice, Nude ,Drug resistance ,Pharmacology ,Biology ,Antiandrogen ,urologic and male genital diseases ,Biochemistry ,03 medical and health sciences ,chemistry.chemical_compound ,Prostate cancer ,Mice ,0302 clinical medicine ,Cell Line, Tumor ,LNCaP ,Nitriles ,Phenylthiohydantoin ,Drug Discovery ,medicine ,Enzalutamide ,Animals ,Humans ,Receptor ,Molecular Biology ,030304 developmental biology ,Cell Proliferation ,0303 health sciences ,Binding Sites ,Prostatic Neoplasms ,Androgen Antagonists ,General Medicine ,medicine.disease ,3. Good health ,Protein Structure, Tertiary ,Androgen receptor ,Molecular Docking Simulation ,chemistry ,Cell culture ,Drug Resistance, Neoplasm ,Receptors, Androgen ,030220 oncology & carcinogenesis ,Benzamides ,Mutagenesis, Site-Directed ,Molecular Medicine - Abstract
Summary There has been a resurgence of interest in the development of androgen receptor (AR) inhibitors with alternative modes of action to overcome the development of resistance to current therapies. We demonstrated previously that one promising strategy for combatting mutation-driven drug resistance is to target the Binding Function 3 (BF3) pocket of the receptor. Here we report the development of a potent BF3 inhibitor, 3-(2,3-dihydro-1 H -indol-2-yl)-1 H -indole, which demonstrates excellent antiandrogen potency and anti-PSA activity and abrogates the androgen-induced proliferation of androgen-sensitive (LNCaP) and enzalutamide-resistant (MR49F) PCa cell lines. Moreover, this compound effectively reduces the expression of AR-dependent genes in PCa cells and effectively inhibits tumor growth in vivo in both LNCaP and MR49F xenograft models. These findings provide evidence that targeting the AR BF3 pocket represents a viable therapeutic approach to treat patients with advanced and/or resistant prostate cancer.
- Published
- 2014
- Full Text
- View/download PDF
5. Characterization of a New Class of Androgen Receptor Antagonists with Potential Therapeutic Application in Advanced Prostate Cancer
- Author
-
Artem Cherkasov, Kate Frewin, Peyman Tavassoli, Paul S. Rennie, Mohamed D.H. Hassona, Emma Tomlinson Guns, Konrad Böhm, Peter Axerio-Cilies, Eric Leblanc, Natalia Kanaan, Huifang Li, Helge Prinz, Kriti Singh, Hans Adomat, and Nathan A. Lack
- Subjects
Male ,Cancer Research ,Databases, Factual ,medicine.drug_class ,Mice, Nude ,Molecular Dynamics Simulation ,Pharmacology ,urologic and male genital diseases ,Antiandrogen ,Benzylidene Compounds ,Prostate cancer ,chemistry.chemical_compound ,Cell Line, Tumor ,Nitriles ,Phenylthiohydantoin ,LNCaP ,Androgen Receptor Antagonists ,Animals ,Humans ,Medicine ,Enzalutamide ,Receptor ,Anthracenes ,Binding Sites ,business.industry ,Androgen ,medicine.disease ,Xenograft Model Antitumor Assays ,Molecular Docking Simulation ,Androgen receptor ,Disease Models, Animal ,Prostatic Neoplasms, Castration-Resistant ,Oncology ,chemistry ,Receptors, Androgen ,Benzamides ,business ,HeLa Cells - Abstract
The human androgen receptor plays a major role in the development and progression of prostate cancer and represents a well-established drug target. All clinically approved androgen receptor antagonists possess similar chemical structures and exhibit the same mode of action on the androgen receptor. Although initially effective, resistance to these androgen receptor antagonists usually develops and the cancer quickly progresses to castration-resistant and metastatic states. Yet even in these late-stage patients, the androgen receptor is critical for the progression of the disease. Thus, there is a continuing need for novel chemical classes of androgen receptor antagonists that could help overcome the problem of resistance. In this study, we implemented and used the synergetic combination of virtual and experimental screening to discover a number of new 10-benzylidene-10H-anthracen-9-ones that not only effectively inhibit androgen receptor transcriptional activity, but also induce almost complete degradation of the androgen receptor. Of these 10-benzylidene-10H-anthracen-9-one analogues, a lead compound (VPC-3033) was identified that showed strong androgen displacement potency, effectively inhibited androgen receptor transcriptional activity, and possesses a profound ability to cause degradation of androgen receptor. Notably, VPC-3033 exhibited significant activity against prostate cancer cells that have already developed resistance to the second-generation antiandrogen enzalutamide (formerly known as MDV3100). VPC-3033 also showed strong antiandrogen receptor activity in the LNCaP in vivo xenograft model. These results provide a foundation for the development of a new class of androgen receptor antagonists that can help address the problem of antiandrogen resistance in prostate cancer. Mol Cancer Ther; 12(11); 2425–35. ©2013 AACR.
- Published
- 2013
- Full Text
- View/download PDF
6. Understanding urinary conditioning film components on ureteral stents: profiling protein components and evaluating their role in bacterial colonization
- Author
-
Hans Adomat, Manoj Monga, Ricardo Miyaoka, Olga Arsovska, Joey Lo, Chelsea Elwood, Emily C. Chou, Ben H. Chew, Adam M. Crowe, Dirk Lange, and Emma Tomlinson-Guns
- Subjects
Adult ,medicine.medical_specialty ,Biomaterial design ,Urinary system ,medicine.medical_treatment ,Urology ,Biocompatible Materials ,Nanotechnology ,Aquatic Science ,Applied Microbiology and Biotechnology ,Bacterial Adhesion ,Mass Spectrometry ,Bacterial colonization ,Humans ,Medicine ,cardiovascular diseases ,Aged ,Water Science and Technology ,business.industry ,Stent ,Ureteral stents ,Middle Aged ,equipment and supplies ,surgical procedures, operative ,Biofilms ,Electrophoresis, Polyacrylamide Gel ,Stents ,Ureter ,business - Abstract
Ureteral stents are fraught with problems. A conditioning film attaches to the stent surface within hours of implantation; however, differences between stent types and their role in promoting encrustation and bacterial adhesion and colonization remain to be elucidated. The present work shows that the most common components do not differ between stent types or patients with the same indwelling stent, and contain components that may drive stent encrustation. Furthermore, unlike what was previously thought, the presence of a conditioning film does not increase bacterial adhesion and colonization of stents by uropathogens. Genitourinary cytokeratins are implicated in playing a significant role in conditioning film formation. Overall, stent biomaterial design to date has been unsuccessful in discovering an ideal coating to prevent encrustation and bacterial adhesion. This current study elucidates a more global understanding of urinary conditioning film components. It also supports specific focus on the importance of physical characteristics of the stent and how they can prevent encrustation and bacterial adhesion.
- Published
- 2013
- Full Text
- View/download PDF
7. Allelic loss of the loci containing the androgen synthesis gene, StAR , is prognostic for relapse in intermediate-risk prostate cancer
- Author
-
Theo H. van der Kwast, Gaetano Zafarana, Jenna Sykes, Jennifer A. Locke, Michael Milosevic, Omer Ahmed, Chad A. Malloff, Emma Tomlinson Guns, Varune Rohan Ramnarine, Wan L. Lam, Alice Meng, Igor Jurisica, Robert G. Bristow, and Melania Pintilie
- Subjects
Oncology ,medicine.medical_specialty ,Pathology ,medicine.drug_class ,Urology ,medicine.medical_treatment ,Abiraterone acetate ,Biology ,Androgen ,medicine.disease ,Androgen deprivation therapy ,Radiation therapy ,Prostate-specific antigen ,chemistry.chemical_compound ,Prostate cancer ,medicine.anatomical_structure ,chemistry ,Prostate ,Internal medicine ,medicine ,Comparative genomic hybridization - Abstract
BACKGROUND Androgen deprivation therapy (ADT) and novel agents targeting the androgen synthesis axis (e.g., abiraterone acetate) are adjuvant therapies that are currently, or may in the future be, combined with radiotherapy to reduce the chance of disease relapse. Little is known about allelic loss or gain pertaining to genes associated with the androgen synthesis axis and whether this is prognostic in patients who receive localized radiotherapy. In this hypothesis generating study, we conducted an array comparative genomic hybridization (aCGH) analysis of 33 androgen synthesis genes to identify potential prognostic factors for radiotherapy outcome. METHODS aCGH analysis of tumor DNA prospectively derived from frozen needle biopsies of 126 men with intermediate-risk disease who underwent image-guided radiotherapy (IGRT) to a mean dose of 76.4 Gy was conducted. Statistical analyses were conducted for allelic loss or gain in genes as potential prognostic factors relative to prostate specific antigen, Gleason-score, and T-category. RESULTS We observed that allelic losses of loci containing the genes StAR and HSD17B2 were associated with increased genetic instability (as determined by percentage genome alteration). On multivariate analyses these loci were prognostic for biochemical disease-free relapse (StAR: HR = 2.84, 95% CI: 1.44–5.61, P = 0.00269; HSD17B2: HR = 1.97, 95% CI: 1.06–3.64, P = 0.031). The results were validated in a surgical cohort of 131 intermediate-risk patients. CONCLUSIONS Allelic losses of the loci containing StAR and HSD17B2 have significant prognostic value for intermediate-risk prostate cancer. With this hypothesis generating information future studies should test StAR and HSD17B2 losses as biomarkers of androgen response in combined modality protocols. Prostate 72:1295–1305, 2012. © 2011 Wiley Periodicals, Inc.
- Published
- 2011
- Full Text
- View/download PDF
8. Antiandrogenic and growth inhibitory effects of ring-substituted analogs of 3,3′-diindolylmethane (Ring-DIMs) in hormone-responsive LNCaP human prostate cancer cells
- Author
-
J. Thomas Sanderson, Stephen Safe, Leela Kotha, Nathan A. Lack, Khalil Abdelbaqi, and Emma Tomlinson Guns
- Subjects
3,3'-Diindolylmethane ,medicine.medical_specialty ,Urology ,Diindolylmethane ,03 medical and health sciences ,chemistry.chemical_compound ,Prostate cancer ,0302 clinical medicine ,Internal medicine ,LNCaP ,medicine ,Viability assay ,030304 developmental biology ,0303 health sciences ,business.industry ,Cancer ,medicine.disease ,3. Good health ,Endocrinology ,Oncology ,chemistry ,030220 oncology & carcinogenesis ,Dihydrotestosterone ,Cancer cell ,Cancer research ,business ,medicine.drug - Abstract
Abdelbaqi K, Lack N, Guns ET, Kotha L, Safe S, Sanderson JT. BACKGROUND : Cruciferous vegetables protect against prostate cancer. Indole-3-carbinol (I3C) and its major metabolite 3,3'-diindolylmethane (DIM), exhibit antitumor activities in vitro and in vivo. Several synthetic ring-substituted dihaloDIMs (ring-DIMs) appear to have increased anticancer activity. METHODS : Inhibition of LNCaP prostate cancer cell growth was measured by a WST-1 cell viability assay. Cytoplasmic and nuclear (...)
- Published
- 2011
- Full Text
- View/download PDF
9. DMSO Represses Inflammatory Cytokine Production from Human Blood Cells and Reduces Autoimmune Arthritis
- Author
-
Michael R. Hughes, Emma Tomlinson Guns, Rachel A. Cederberg, Vivian Lam, Kelly M. McNagny, Hisae Nakamura, Ingrid Elisia, Jessica Cait, Hans Adomat, Leorra Lee, Gerald Krystal, and Ismael Samudio
- Subjects
medicine.medical_specialty ,Chemistry ,Dimethyl sulfoxide ,medicine.medical_treatment ,p38 mitogen-activated protein kinases ,Pharmacology ,Biochemistry ,chemistry.chemical_compound ,Cytokine ,Endocrinology ,Mechanism of action ,In vivo ,Internal medicine ,Genetics ,medicine ,Viability assay ,medicine.symptom ,Molecular Biology ,PI3K/AKT/mTOR pathway ,Ex vivo ,Biotechnology - Abstract
Dimethyl sulfoxide (DMSO) is currently being used by many people, both topically and orally, to treat inflammatory conditions as well as cancer. However, little is known about the efficacy, safety and mechanism of action of DMSO in humans. We therefore examined the effects of this polar solvent on whole human blood, stimulated or not, ex vivo, with E. coli. We found that, between 1 and 2%, DMSO markedly inhibited cytokine production without affecting cell viability. However, at greater than 5%, significant death of leukocytes was observed, suggesting that DMSO has only a narrow window of efficacy. The two in vivo generated metabolites of DMSO, dimethyl sulfide (DMS) and dimethylsulfone (DMSO2), required higher concentrations than DMSO to be anti-inflammatory. Mechanism of action studies using purified human monocytes revealed that DMSO's anti-inflammatory properties were due, at least in part, to inhibition of the ERK1/2, p38, PI3K and JNK pathways. In vivo mouse model studies revealed that topical admini...
- Published
- 2015
- Full Text
- View/download PDF
10. Age-dependent alterations of the kynurenine pathway in the YAC128 mouse model of Huntington disease
- Author
-
Emma Tomlinson Guns, Hans Adomat, Ge Lu, David P. Budac, Thomas Möller, Gelareh Mazarei, and Blair R. Leavitt
- Subjects
Male ,medicine.medical_specialty ,Cerebellum ,Aging ,Serotonin ,Huntingtin ,Kynurenine pathway ,Genotype ,Striatum ,Biology ,Biochemistry ,Pathogenesis ,Cellular and Molecular Neuroscience ,chemistry.chemical_compound ,Mice ,Internal medicine ,medicine ,Animals ,Indoleamine-Pyrrole 2,3,-Dioxygenase ,Indoleamine 2,3-dioxygenase ,Kynurenine ,Tryptophan ,Brain ,Quinolinic Acid ,Corpus Striatum ,Tryptophan Oxygenase ,medicine.anatomical_structure ,Endocrinology ,Huntington Disease ,chemistry ,Female ,Quinolinic acid ,Signal Transduction - Abstract
Indoleamine 2,3 dioxygenase (Ido1), the first and rate-limiting enzyme of the kynurenine pathway (KP), is a striatally enriched gene with increased expression levels in the YAC128 mouse model of Huntington disease (HD). Our objective in this study was to delineate age-related KP alterations in this model. Three enzymes potentially catalyze the first step of the KP; Ido1 and Indoleamine 2,3 dioxygenase-2 were highly expressed in the striatum and Tryptophan 2,3 dioxygenase (Tdo2) in the cerebellum. During development, Ido1 mRNA expression is dynamically regulated and chronically up-regulated in YAC128 mice. Kynurenine (Kyn) to tryptophan (Trp) ratio, a measure of activity in the first step of the KP, was elevated in YAC128 striatum, but no change in Tdo2 mRNA levels or Kyn to Trp ratio was detected in the cerebellum. Ido1 induction was coincident with Trp depletion at 3 months and Kyn accumulation at 12 months of age in striatum. Changes in downstream KP metabolites of YAC128 mice generally followed a biphasic pattern with neurotoxic metabolites reduced at 3 months and increased at 12 months of age. Striatally specific induction of Ido1 and downstream KP alterations suggest involvement in HD pathogenesis, and should be taken into account in future therapeutic developments for HD.
- Published
- 2013
11. Targeting the binding function 3 (BF3) site of the androgen receptor through virtual screening. 2. development of 2-((2-phenoxyethyl) thio)-1H-benzimidazole derivatives
- Author
-
Eric Leblanc, Peter Axerio-Cilies, Artem Cherkasov, Kriti Singh, Christophe Labriere, Huifang Li, Fuqiang Ban, Ravi Shashi Nayana Munuganti, Mohamed D.H. Hassona, Robert N. Young, Emma Tomlinson Guns, Paul S. Rennie, Nathan A. Lack, and Kate Frewin
- Subjects
Male ,Virtual screening ,Binding Sites ,Bicalutamide ,Molecular Structure ,Androgen binding ,Pharmacology ,Prostate-Specific Antigen ,Crystallography, X-Ray ,Flutamide ,Androgen receptor ,chemistry.chemical_compound ,chemistry ,Receptors, Androgen ,Cell Line, Tumor ,Drug Discovery ,Nilutamide ,LNCaP ,medicine ,Molecular Medicine ,Enzalutamide ,Humans ,Benzimidazoles ,medicine.drug - Abstract
The human androgen receptor (AR) is a proven therapeutic target in prostate cancer. All current antiandrogens, such as Bicalutamide, Flutamide, Nilutamide, and Enzalutamide, target the buried hydrophobic androgen binding pocket of this protein. However, effective resistance mechanisms against these therapeutics exist such as mutations occurring at the target site. To overcome these limitations, the surface pocket of the AR called binding function 3 (BF3) was characterized as an alternative target for small molecule therapeutics. A number of AR inhibitors directly targeting the BF3 were previously identified by us ( J. Med. Chem. 2011 . 54 , 8563 ). In the current study, based on the prior results, we have developed structure-activity relationships that allowed designing a series of 2-((2-phenoxyethyl)thio)-1H-benzimidazole and 2-((2-phenoxyethyl)thio)-1H-indole as lead BF3 inhibitors. Some of the developed BF3 ligands demonstrated significant antiandrogen potency against LNCaP and Enzalutamide-resistant prostate cancer cell lines.
- Published
- 2013
12. Targeting the Binding Function 3 (BF3) Site of the Human Androgen Receptor Through Virtual Screening
- Author
-
K.H. Chan, Frank Q. Han, Peter Axerio-Cilies, R. Kiplin Guy, Emma Tomlinson Guns, Nathan A. Lack, Paul S. Rennie, Clementine Feau, Artem Cherkasov, Eric Leblanc, and Peyman Tavassoli
- Subjects
Models, Molecular ,Databases, Factual ,Transcription, Genetic ,Protein Conformation ,In silico ,Quantitative Structure-Activity Relationship ,Pharmacology ,Crystallography, X-Ray ,Ligands ,Article ,Small Molecule Libraries ,Prostate cancer ,Cell Line, Tumor ,Drug Discovery ,medicine ,Humans ,Binding site ,Receptor ,Cytotoxicity ,Virtual screening ,Binding Sites ,Chemistry ,Androgen Antagonists ,medicine.disease ,Androgen receptor ,Mechanism of action ,Receptors, Androgen ,Mutation ,Molecular Medicine ,medicine.symptom - Abstract
The androgen receptor (AR) is the best studied drug target for the treatment of prostate cancer. While there are a number of drugs that target the AR, they all work through the same mechanism of action and are prone to the development of drug resistance. There is a large unmet need for novel AR inhibitors which work through alternative mechanism(s). Recent studies have identified a novel site on the AR called Binding Function 3 (BF3) that is involved into AR transcriptional activity. In order to identify inhibitors that target the BF3 site, we have conducted a large-scale in-silico screen followed by experimental evaluation. A number of compounds were identified that effectively inhibited the AR transcriptional activity with no obvious cytotoxicity. The mechanism of action of these compounds was validated by biochemical assays and x-ray crystallography. These findings lay a foundation for the development of alternative or supplementary therapies capable of combating prostate cancer even in its anti-androgen resistant forms.
- Published
- 2011
13. Rh2 or its aglycone aPPD in combination with docetaxel for treatment of prostate cancer
- Author
-
Emma Tomlinson Guns, Andy Eberding, William Jia, Alain G. Musende, Euan Ramsay, and Marcel B. Bally
- Subjects
Oncology ,Male ,medicine.medical_specialty ,Combination therapy ,Ginsenosides ,Urology ,Mice, Nude ,Antineoplastic Agents ,Apoptosis ,Docetaxel ,urologic and male genital diseases ,Prostate cancer ,Mice ,DU145 ,In vivo ,Prostate ,Internal medicine ,Cell Line, Tumor ,LNCaP ,medicine ,Animals ,Humans ,neoplasms ,Cell Proliferation ,Analysis of Variance ,Dose-Response Relationship, Drug ,business.industry ,Cancer ,Prostatic Neoplasms ,medicine.disease ,Endocrinology ,medicine.anatomical_structure ,Drug Therapy, Combination ,Taxoids ,business ,therapeutics ,medicine.drug ,Drugs, Chinese Herbal - Abstract
BACKGROUND Docetaxel is one of the few chemotherapeutic drugs that are considered highly effective when used to treat prostate cancer patients that have relapsed and/or metastatic disease, it is therefore reasonable to expect further improvements in treatment outcomes when it is combined with other therapeutic agents active in prostate cancer. This study assesses the combination of well tolerated and orally bioavailable formulations of ginsenoside Rh2 or its aglycone aPPD with docetaxel. METHODS The in vitro activity of Rh2, aPPD, and docetaxel was determined in four prostate cancer cell lines: PC-3, LNCaP, DU145, and C4-2. Combinations of Rh2 or aPPD with docetaxel were assessed using the constant ratio combination design. Combination Indices (CI) and Dose Reduction Indices (DRI) were subsequently estimated using Calcusyn™. In vivo efficacy studies and Immunohistochemical analyses (PC-3 model) were also evaluated. RESULTS In PC-3, DU145 and C4-2 prostate cancer cells combinations of Rh2 or aPPD with docetaxel were predominantly additive or synergistic. Combinations of Rh2 + docetaxel and aPPD + docetaxel caused established PC-3 tumors to regress from their initial size by 15% and 27%, respectively. Tumor cell proliferation rate (measured by Ki-67 positive cells) was significantly lower for combinations of Rh2 + docetaxel and aPPD + docetaxel, compared to animals treated with docetaxel alone. CONCLUSIONS Rh2 and aPPD can be combined with docetaxel to yield additive or synergistic activity in vitro and in vivo. Pending further assessment of toxicity and pharmacodynamic behavior, this study supports testing of combinations of ginsenoside Rh2 or its aglycone aPPD with docetaxel in a clinical setting. Prostate 70: 1437–1447, 2010. © 2010 Wiley-Liss, Inc.
- Published
- 2010
14. Pre-clinical evaluation of Rh2 in PC-3 human xenograft model for prostate cancer in vivo: formulation, pharmacokinetics, biodistribution and efficacy
- Author
-
Hans Adomat, William Jia, Emma Tomlinson Guns, Andy Eberding, Catherine A. Wood, Antonio Hurtado-Coll, Marcel B. Bally, Alain G. Musende, and Ladan Fazli
- Subjects
Male ,Cancer Research ,medicine.medical_specialty ,Biodistribution ,Ginsenosides ,Administration, Oral ,Mice, Nude ,Antineoplastic Agents ,Apoptosis ,Docetaxel ,Toxicology ,Prostate cancer ,Mice ,Pharmacokinetics ,Drug Stability ,Oral administration ,In vivo ,Internal medicine ,Cell Line, Tumor ,Medicine ,Distribution (pharmacology) ,Animals ,Humans ,Pharmacology (medical) ,Tissue Distribution ,Aspartate Aminotransferases ,Pharmacology ,business.industry ,Body Weight ,Animal Structures ,Prostatic Neoplasms ,Alanine Transaminase ,medicine.disease ,Antineoplastic Agents, Phytogenic ,Xenograft Model Antitumor Assays ,Endocrinology ,Ki-67 Antigen ,Treatment Outcome ,Oncology ,Solubility ,Creatinine ,Toxicity ,Solvents ,Taxoids ,business ,medicine.drug - Abstract
This study assesses the pharmacokinetics, biodistribution and efficacy of ginsenoside Rh2 as a single agent administered in a novel oral dosage formulation.A novel oral dosage formulation of Rh2 has been described. Rh2 levels in blood and tissues following administration to nu/nu nude mice were determined by high performance liquid chromatography tandem mass spectroscopy. Efficacy was determined in an established PC-3 human prostate cancer model.Rh2 administered at a dose of 120 mg/kg exhibited a peak plasma concentration of 19.0 +/- 2.0 microg/ml. Rh2 levels were measurable in prostate and tumor tissues, with as much as 0.3% of the administered dose being detected in tumors. This formulation exhibited no measurable toxicity as judged by weight loss or changes in serum levels of aspartate aminotransferase, alanine aminotransferase, and creatinine. This dose engendered a significant delay in PC-3 tumor growth, an increase in apoptotic index, and a decrease in tumor cell proliferation.Rh2 is a stable compound that can be formulated for oral gavage. Pharmacokinetics studies demonstrate its ability to be absorbed following oral administration. Future studies will assess the pharmacokinetics of Rh2 when administered in combination with docetaxel.
- Published
- 2008
15. Abstract 3654: Targeting binding function-3 site on the androgen receptor to treat Enzalutamide-resistant prostate cancer
- Author
-
Paul S. Rennie, Ravi Shashi Nayana Munuganti, Artem Cherkasov, Emma Tomlinson Guns, Eric Leblanc, and Mohamed Dh Hassona
- Subjects
Cancer Research ,business.industry ,Cancer ,Pharmacology ,medicine.disease ,TMPRSS2 ,Androgen receptor ,Prostate cancer ,chemistry.chemical_compound ,Oncology ,Mechanism of action ,chemistry ,LNCaP ,medicine ,Enzalutamide ,medicine.symptom ,Receptor ,business - Abstract
Interest in developing androgen receptor (AR) inhibitors with novel mechanism of action is on the rise since the commercial anti-androgens (including recently approved drug, Enzalutamide) face clinical limitations. The current therapies fail over a period of time because they all target mutation-prone hormone binding pocket on AR to which the receptor has already developed effective resistance mechanisms. Hence, there is a pressing need for novel therapeutics that inhibit the AR through alternative modes of action. Recent studies have identified a novel binding pocket on the surface of AR called binding function-3 (BF3) that is critical for the AR transcriptional activity. In order to develop promising drug-like candidates, we performed structural optimization of our lead AR BF3 inhibitor, followed by a series of experimental validation of the synthetic analogues. As a result, we have discovered a chemical series of quinoline as new lead BF3 inhibitors. One of the most potent inhibitors identified, VPC-13566, demonstrated an IC50 of 0.071μM in AR eGFP transcriptional assay. Confirming it as a true BF3 binder, VPC-13566 displaced Bag-1L peptide, a co-regulator protein that binds to AR BF3 pocket. Additionally, the Biolayer Interferometry assay detected direct reversible interactions between the AR ligand binding domain and the inhibitor. To confirm VPC-13566 binding to the BF3 pocket, a mutagenesis study was performed. Results with mutants F673E, E837A and N833W confirmed that compound did not show any binding to the protein compared with the wild type in a BLI assay. VPC-13566 demonstrated strong anti-proliferative activity against LNCaP and Enzalutamide-resistant prostate cancer cell lines (MR49F) whereas it did not affect the growth of AR independent PC3 cell line. It also reduced prostate specific antigen (PSA) in both LNCaP and MR49F and reduced expression of AR target genes, PSA and TMPRSS2. These findings suggest that VPC-13566 exhibits AR BF3 specific mechanism of action. Furthermore, VPC-13566 significantly reduced AR-dependent growth of tumors and PSA levels in LNCaP and MR49F xenograft models. Based on these outcomes, it can be anticipated that such drug prototypes will lay a foundation for the development of alternative or supplementary small-molecule therapies capable of combating PCa even in its drug resistant forms. Because the emergence of castration resistance is the lethal end stage of the disease, we anticipate that the proposed research will eventually have a substantial impact on patient survival. Citation Format: Ravi Shashi Nayana Munuganti, Mohamed DH Hassona, Eric Leblanc, Emma T. Guns, Paul S. Rennie, Artem Cherkasov. Targeting binding function-3 site on the androgen receptor to treat Enzalutamide-resistant prostate cancer. [abstract]. In: Proceedings of the 106th Annual Meeting of the American Association for Cancer Research; 2015 Apr 18-22; Philadelphia, PA. Philadelphia (PA): AACR; Cancer Res 2015;75(15 Suppl):Abstract nr 3654. doi:10.1158/1538-7445.AM2015-3654
- Published
- 2015
- Full Text
- View/download PDF
16. Abstract 1778: Selectively targeting the DNA-binding domain of the androgen receptor as a prospective therapy for prostate cancer
- Author
-
Mani Roshan-Moniri, Huifang Li, Fuqiang Ban, Kriti Singh, Michael Hsing, Paul S. Rennie, Mohamed Dh Hassona, Kush Dalal, Emma Tomlinson Guns, Aishwariya Sharma, Eric Leblanc, Artem Cherkasov, and Scott M. Dehm
- Subjects
Cancer Research ,medicine.medical_specialty ,medicine.drug_class ,Chemistry ,DNA-binding domain ,Androgen ,medicine.disease ,Chromatin ,Androgen receptor ,Prostate cancer ,Endocrinology ,Oncology ,Nuclear receptor ,Internal medicine ,LNCaP ,medicine ,Cancer research ,Transcription factor - Abstract
The androgen receptor (AR) is a hormone-activated transcription factor implicated in the development and progression of prostate cancer. The AR contains an N-terminal domain (NTD), followed by DNA binding (DBD) and ligand-binding (LBD) domains. Upon binding of androgens to the LBD, the AR moves into the nucleus where it interacts with target genes via the conserved AR-DBD. Prostate cancer treatment involves the use of small-molecules to block androgen production or to compete with androgens for binding to the AR-LBD. Drug-resistance occurs when LBD mutations render small-molecule treatment ineffective or when constitutively active AR splice variants, lacking the LBD, become overexpressed. We recently identified a surface pocket on the AR-DBD that may serve as an alternative drug-target site. The DBD-specific, small molecule compounds presented here block transcriptional activity of full-length and splice variant AR forms across multiple cell lines and show no cross-reactivity with related steroid nuclear receptors. The inhibition is lost when residues in the binding pocket are mutated or when the AR-DBD is replaced with a different DNA binding domain. Biophysical techniques were used to explore the interaction of these compounds with the purified, recombinant DBD protein. Gene expression analysis demonstrated the down-regulation of AR target genes following compound treatment, without any obvious expression signature associated with toxicity. The compounds affected DNA binding in vitro and also blocked interactions of the AR with chromatin inside the nucleus. Finally, the lead compound suppressed the growth of LNCaP tumor xenografts and was accompanied by down-regulation of AR target genes, such as PSA. These results suggest a mechanism whereby our developed inhibitory compounds interfere with DNA binding by the AR, potentially leading to effective treatment of advanced, castration-resistant prostate cancers. Citation Format: Kush Dalal, Mani Roshan-Moniri, Aishwariya Sharma, Huifang Li, Fuqiang Ban, Mohamed D. Hassona, Michael Hsing, Kriti Singh, Eric LeBlanc, Scott Dehm, Emma Tomlinson Guns, Artem Cherkasov, Paul S. Rennie. Selectively targeting the DNA-binding domain of the androgen receptor as a prospective therapy for prostate cancer. [abstract]. In: Proceedings of the 106th Annual Meeting of the American Association for Cancer Research; 2015 Apr 18-22; Philadelphia, PA. Philadelphia (PA): AACR; Cancer Res 2015;75(15 Suppl):Abstract nr 1778. doi:10.1158/1538-7445.AM2015-1778
- Published
- 2015
- Full Text
- View/download PDF
17. Assessment of the antitumor activity of leech (huridinaria manillensis) saliva extract in prostate cancer
- Author
-
Abdulrahman Abdualkader, Amr Ammar, Mohamed Alaama, Ahmed Merzouk, Mei Chin, Mohamed Hessein, Omer Kucuk, Abbas Mohammad Ghawi, Abul Bashar Mohammed Helaluddin, and Emma Tomlinson Guns
- Subjects
Antitumor activity ,Cancer Research ,Saliva ,Prostate cancer ,animal structures ,Oncology ,business.industry ,Medicine ,Leech ,Pharmacology ,business ,medicine.disease - Abstract
e16120 Background: Ancient traditional physicians from many countries used leeching to treat a wide range of diseases for thousands of years. Leech saliva contains a large number of peptides and pr...
- Published
- 2015
- Full Text
- View/download PDF
18. Abstract 2508: The development of anti-androgens with a novel mechanism of action for treatment of castration-resistant prostate cancer
- Author
-
Emma Tomlinson Guns, Fuqiang Ban, Ravi Shashi Nayana Munuganti, Paul S. Rennie, Eric Leblanc, Mohamed D.H. Hassona, and Artem Cherkasov
- Subjects
Cancer Research ,business.industry ,Anti-Androgen ,medicine.disease ,TMPRSS2 ,Androgen receptor ,Prostate cancer ,Oncology ,Mechanism of action ,Castration Resistance ,Immunology ,Coactivator ,LNCaP ,Cancer research ,Medicine ,medicine.symptom ,business - Abstract
The androgen receptor (AR) is one of the most validated therapeutic targets in prostate cancer (PCa). Conventional anti-androgens lose effectiveness as cancer therapeutics because anti-androgen resistance usually develops after long term treatment. The challenge is that the current therapeutics bind to the same site of the AR (hormone binding pocket) and act via the same mode, to which the receptor has already developed effective resistance mechanisms. Hence, there is a pressing need for novel therapeutics that inhibit the AR through novel, alternative modes of action. Recent studies have identified a novel binding pocket on the surface of AR called binding function 3 (BF3) that is important for the AR transcriptional activity. In order to identify compounds that specifically bind to BF3 site and inhibit the AR, we conducted a systematic in silico screen (that included large-scale docking, in-site rescoring, and consensus voting procedures) followed by experimental validation of the identified hit molecules. As a result, we have discovered a novel chemical series of indoles as lead BF3 inhibitors. One of the most potent inhibitors identified, VPC-13163, demonstrated an IC50 of 0.31µM in AR eGFP transcriptional assay. Confirming it as a true BF3 binder, VPC-13163 neither displaced the co-activator from an alternative coactivator binding site, activation function 2 site, nor androgen from the hormone binding pocket. Additionally, the Biolayer Interferometry assay detected direct reversible interactions between the AR ligand binding domain and the inhibitor. VPC-13163 demonstrated strong anti-proliferative activity against LNCaP and Enzalutamide-resistant prostate cancer cell lines (MR49F) whereas it did not affect the growth of AR independent PC3 cell line. It also inhibits prostate specific antigen (PSA) in both LNCaP and MR49F and reduces expression of AR target genes, PSA and TMPRSS2. These findings suggest that VPC-13163 exhibits AR BF3 specific mechanism of action. Furthermore, VPC-13163 reduces AR-dependent growth of xenograft tumors in vivo. Based on these outcomes, it can be anticipated that such drug prototypes will lay a foundation for the development of alternative or supplementary small-molecule therapies capable of combating PCa even in its drug resistant forms. Because the emergence of castration resistance is the lethal end stage of the disease, we anticipate that the proposed research will eventually have a substantial impact on patient survival. Citation Format: Ravi Shashi Nayana Munuganti, Mohamed DH Hassona, Eric Leblanc, Fuqiang Ban, Emma T. Guns, Paul S. Rennie, Artem Cherkasov. The development of anti-androgens with a novel mechanism of action for treatment of castration-resistant prostate cancer. [abstract]. In: Proceedings of the 105th Annual Meeting of the American Association for Cancer Research; 2014 Apr 5-9; San Diego, CA. Philadelphia (PA): AACR; Cancer Res 2014;74(19 Suppl):Abstract nr 2508. doi:10.1158/1538-7445.AM2014-2508
- Published
- 2014
- Full Text
- View/download PDF
19. Abstract 1632: Discovery of a novel series of androgen receptor antagonists with potential therapeutic applications in castration-resistant prostate cancer
- Author
-
Mohamed D.H. Hassona, Peter Axerio-Cilies, Paul S. Rennie, Artem Cherkasov, Emma Tomlinson Guns, Nathan A. Lack, Huifang Li, and Eric Leblanc
- Subjects
Cancer Research ,Bicalutamide ,medicine.drug_class ,business.industry ,Androgen binding ,Pharmacology ,medicine.disease ,Androgen ,Androgen receptor ,Prostate cancer ,chemistry.chemical_compound ,Oncology ,chemistry ,LNCaP ,medicine ,Enzalutamide ,Androgen Receptor Antagonists ,business ,medicine.drug - Abstract
The human androgen receptor (AR) represents a well-established drug target for prostate cancer treatment. All clinically used antiandrogens, such as Bicalutamide and Enzalutamide, possess similar chemical structures and bind to the AR in the androgen binding site (ABS). These AR antagonists are initially effective, but resistance invariably developed in the castration-resistant prostate cancer (CRPC). Even in late-stage patients, the AR activity is still persistent in the progression of the disease. Thus, there is a continuing need for novel chemical classes of AR antagonists that could overcome the drug resistance. In this study, we performed a virtual screening against the AR ABS, and identified novel AR antagonists with chemical structures completely different from existing antiandrogens. A 10-(4-Hydroxybenzylidene)anthracen-9(10H)-one compound was discovered that not only effectively inhibits AR transcription and strongly displaces androgen in the ABS, but induces AR degradation in prostate cancer cells. Starting from the initial hit compound, a series of 10-benzylidene-10H-anthracen-9-ones were synthesized and evaluated by in vitro assays. A close analogue with enhanced potency was identified as a lead compound, which demonstrated strong androgen displacement potency, effective AR transcriptional inhibition, and a profound ability to cause degradation of AR. Notably, it exhibited significant activity against MDV3100-resistant prostate cancer cells. This lead compound was evaluated in both non-castrated and castration-resistant LNCaP xenograft models, and demonstrated significant effect on inhibiting tumor growth and reducing prostate specific antigen (PSA). This series of compounds were predicted to adopt a different binding mode from current antiandrogens, which may circumvent the resistance rendered by identified gain-of-function mutations. Further development of this series of AR antagonists may have great therapeutic potential in CRPC. Citation Format: Huifang Li, Mohamed DH Hassona, Nathan A. Lack, Peter Axerio-Cilies, Eric Leblanc, Emma T. Guns, Paul S. Rennie, Artem Cherkasov. Discovery of a novel series of androgen receptor antagonists with potential therapeutic applications in castration-resistant prostate cancer. [abstract]. In: Proceedings of the 105th Annual Meeting of the American Association for Cancer Research; 2014 Apr 5-9; San Diego, CA. Philadelphia (PA): AACR; Cancer Res 2014;74(19 Suppl):Abstract nr 1632. doi:10.1158/1538-7445.AM2014-1632
- Published
- 2014
- Full Text
- View/download PDF
20. Abstract 1070: New potent inhibitors of the androgen receptor that target its BF3 surface binding site
- Author
-
Peter Axerio, Kate Frewin, Eric Leblanc, Paul S. Rennie, Ravi Shashi Nayana Munuganti, Huifang Li, Fuqiang Ban, Emma Tomlinson Guns, and Artem Cherkasov
- Subjects
Androgen receptor ,Cancer Research ,medicine.medical_specialty ,Endocrinology ,Oncology ,Chemistry ,Internal medicine ,medicine ,Cancer research ,Surface binding - Abstract
In the development and progression of prostate cancer, the androgen receptor (AR) plays a critical role and its hormone/ligand-binding site is the primary therapeutic target for all antiandrogens (eg Bicalutamide, MDV3100) currently used to treat advanced, metastatic forms of this disease. While treatment with these AR inhibitors initially suppresses prostate tumor growth, resistance to these drugs invariably emerges. Accordingly, there exists a clinical need for the development of new AR antagonists with different chemical structures and different mechanisms of action for targeting and inhibiting AR transactivation. To this end, we have focused on a surface pocket on the AR called Binding Function 3 (BF3). Applying iterative in silico screening to millions of chemicals in the ZINC database, coupled with biological screening for AR binding and activity, we identified several compounds that can bind directly to the BF3 pocket and inhibit AR transactivation. Cell-based screening assays for inhibition of a fluorescent ARE-reporter and PSA expression, together with Biolayer Interferometry analysis for measuring binding to the AR, revealed several chemically distinct BF-3 binders that showed significant IC50 inhibitions of the AR in the nano-molar to low micro-molar range. Validation for binding to the BF3 site was performed by x-ray crystallography. Furthermore, none of these compounds were able to displace DHT from the hormone binding site even at concentrations more than 10-fold higher than their IC50 values. In addition to wild type LNCaP prostate cancer cells, these BF3 binders effectively inhibited cell proliferation (MTS assay) and PSA expression in derived MDV3100-resistant prostate cancer cell lines, but had no effect on cell viability of AR-negative prostate cancer cell lines. In summary, we have identified an entirely new class of anti-androgens that bind to the BF3 surface site of the AR and inhibit its transactivation by a mechanism which does not involve binding to its hormone/ligand binding site and thereby bypasses the treatment resistance seen with conventional antiandrogens. (Supported by funds from the PCF, Canada Safeway, and CIHR). Citation Format: Ravi Munuganti, Fuqiang Ban, Huifang Li, Eric LeBlanc, Peter Axerio, Kate Frewin, Emma Tomlinson Guns, Artem Cherkasov, Paul S. Rennie. New potent inhibitors of the androgen receptor that target its BF3 surface binding site. [abstract]. In: Proceedings of the 104th Annual Meeting of the American Association for Cancer Research; 2013 Apr 6-10; Washington, DC. Philadelphia (PA): AACR; Cancer Res 2013;73(8 Suppl):Abstract nr 1070. doi:10.1158/1538-7445.AM2013-1070
- Published
- 2013
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.